Arkolith/Insider Trading/NMRA/Form 4

Berns Paul L

See Remarks, DirectorNeumora Therapeutics, Inc. (NMRA) · full profile →Form 4 · filed Feb 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$34K
Net Open-Market Flow
-$34K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 17, 2026Sell(S)10K$3.51$34K7.4M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000052) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML